Published in AIDS Weekly, October 2nd, 1995
The trial, ACTG 175, showed that all treatments studied - ddI plus AZT, ddC plus AZT, and ddI alone - were superior to AZT monotherapy in delaying progression to AIDS, death, or precipitous decline of CD4+ T cells in patients with intermediate HIV disease (initial CD4 counts of 200 to 500 cells/(mu)L). The newer treatments provided a greater...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.